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BRIEF CLINICAL REPORTSDelayed migration of a transfemorally implanted aortic bioprosthesisCostin Radu, MD,a Richard Raffoul, MD,a Eric Brochet, MD,b and Dominique Himbert, MD,b Paris, FranceTranscatheter aortic valve implantation has expanded the
possibilities of treatment of aortic stenosis to patients con-
sidered at too high risk for aortic valve replacement. We re-
port the delayed migration of a transfemorally implanted
aortic bioprosthesis and discuss the potential causes of
this complication.CLINICAL SUMMARY
An 85-year-old-man with symptomatic aortic stenosis
was referred for transcatheter aortic valve implantation.
He had a history of diabetes, hypertension, peripheral vas-
cular disease, and patent coronary artery bypass grafts.
Transthoracic echocardiography (TTE) and transesopha-
geal echocardiography revealed a moderately calcified tri-
cuspid aortic valve with area of 0.6 cm2, mean gradient of
39 mm Hg, subvalvular nonobstructive septal hypertrophy
measured at 16 mm, pulmonary artery systolic pressure of
40 mm Hg, and left ventricular ejection fraction of 45%.
Aortic valve calcification score according to computed to-
mographic scan was 2980 Agatston units. The logistic
EuroSCORE was 26%, and the Society of Thoracic Sur-
geons Predicted Risk of Mortality was 9%. Aortic annulus
diameter was measured at 20 mm on TTE and transesopha-
geal echocardiography and at 21.4326.1 mm on computed
tomographic scan. Femoroiliac vessels were suitable for the
transfemoral approach.
The procedure was performed under fluoroscopic guid-
ance, as detailed previously elsewhere, with the patient un-
der locoregional anesthesia.1,2 Briefly, after insertion of the
closing device in the left common femoral artery (Prostar;
Abbott Vascular, Santa Clara, Calif), retrograde crossing,
and predilatation of the native valve, a 23-mm SapienXT
prosthesis (Edwards Lifesciences Inc, Irvine, Calif) was
positioned within the aortic valve and delivered by balloon
inflation under rapid ventricular pacing. The prosthesis
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(Figure 1). The patient was in stable condition, and after
24 hours in the intensive care unit, TTE revealed a mean
gradient of 19 mm Hg, good left ventricular function,
and no aortic regurgitation. Hypertension was well
controlled with nicardipine hydrochloride (INN nicardi-
pine) administered intravenously in the intensive care
unit and with valsartan and furosemide thereafter. At post-
operative day 5, the predischarge TTE revealed that the
prosthesis had migrated into the left ventricular outflow
tract beneath the level of the native valve, which was func-
tioning without aortic regurgitation (Figure 2). The condi-
tion was well tolerated hemodynamically, but the
bioprosthesis was hindering the anterior leaflet of the mi-
tral valve. Reoperation was decided by the medicosurgical
team. Transesophageal echocardiography and surgical
findings confirmed the TTE findings (Figure 2). The pros-
thesis was easily removed. The aortic annulus was mea-
sured with Hegar dilators at 24 mm. The cusps were
removed, and a 23-mm Epic (St Jude Medical, Inc, St
Paul, Minn) bioprosthesis was implanted. The postopera-
tive course was uneventful.DISCUSSION
Late migration toward the left ventricle of 2 transapically
implanted bioprosthesis in a single patient has been re-
ported, but in that case the first valve may have been im-
planted in a slightly too ventricular position.3 In another
report, a patient with a severely calcified aortic annulus
and normally functioning bileaflet mechanical mitral pros-
thesis had late upward displacement of a transapically im-
planted aortic bioprosthesis.4
In our case, migration of the bioprosthesis must have oc-
curred late and gradually because there was no aortic re-
gurgitation immediately after the implantation according
to either angiography or TTE, and when patient left the in-
tensive care unit the prosthesis was correctly positioned
with no aortic regurgitation. The subvalvular septal hyper-
trophy could be incriminated for the postprocedural gradi-
ent. Moreover, it might have prevented further migration of
the bioprosthesis in the left ventricular cavity. The most
likely explanation for this migration might be the underes-
timation of the annular size by echocardiographic and
computed tomographic measurements. The valve size
was chosen in accordance with echocardiographic mea-
surements, which is our preferred method, although we
acknowledge that a gold standard does not exist. Undersiz-
ing may not be the only explanation, however, because
there was no aortic regurgitation and the valve did notardiovascular Surgery c Volume 143, Number 1 e1
FIGURE 1. Aortography (A) and transthoracic echocardiography (B) at implantation showing correct positioning of the prosthesis and absence of signif-
icant aortic regurgitation. Arrow shows the inferior limit of the prosthesis; bar depicts the position of the anterior mitral leaflet.
Brief Clinical Reportsmigrate immediately. Moreover, a moderately calcified
valve might provide less support for the bioprosthesis, be-
cause fixation of percutaneous valves occurs at the annulus
and on the entire length of the calcified cusps. In our case,
the aortic valve appeared only moderately calcified on
echocardiography and fluoroscopy. The Agatston score
was relatively high at 2980 units but was still in the mod-
erate range for severe aortic stenosis. More oversizing
might be considered in scarcely calcified valves but must
be balanced against the risk of annular rupture.FIGURE 2. Transthoracic echocardiography (A) and computed tomographic s
tract, hindering the anterior mitral leaflet.Arrowhead indicates native aortic valv
the anterior mitral leaflet. Transesophageal echocardiography (C) and operative
valve, which presents only moderate calcifications.
e2 The Journal of Thoracic and Cardiovascular SurgeHypothetically, a CoreValve (Medtronic, Inc, Minneapolis,
Minn) device might be more adapted in this situation, be-
cause it has a longer stent providing a longer area of fixa-
tion, but this has not been proved.
This complication emphasizes the importance of accu-
rate measurement of the aortic annulus before transcatheter
aortic valve implantation to avoid undersizing. The migra-
tion could have subsequently resulted in severe aortic regur-
gitation or lesions of the mitral valve. Interestingly, our
patient was symptom free, which underlines the importancecan (B) showing migration of the prosthesis in the left ventricular outflow
e; arrow shows the inferior limit of the prosthesis; bar depicts the position of
view (D) confirming the migration of the prosthesis below the native aortic
ry c January 2012
Brief Clinical Reportsof a thorough predischarge checkup after transcatheter aor-
tic valve implantation even in symptom-free patients.References
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935-7.Pulmonary vein thrombosis after video-assisted thoracoscopic left
upper lobectomyKazuto Ohtaka, MD, Yasuhiro Hida, MD, PhD, Kichizo Kaga, MD, PhD, Yasuaki Iimura, MD, PhD,
Nobuyuki Shiina, MD, Jun Muto, MD, and Satoshi Hirano, MD, PhD, Sapporo, JapanThrombus in the stump of the pulmonary vein (PV) after
lung resection is a rare but lethal complication. Only 3 case
reports have described radiographically detected thrombus
in the stump of the PV.1-3 Thrombus in the systemic
circulation can result in infarction of the brain, kidneys,
and spleen. We describe 3 patients with thrombus in the
stump of the PV after video-assisted thoracoscopic left up-
per lobectomy.CASE REPORTS
Patient 1
A shadow was evident in the left upper lung field in the
routine screening chest x-ray of a 64-year-old woman who
was a nonsmoker with a medical history of chronic atrial
fibrillation. Chest computed tomography (CT) showed
a mass 31 mm in diameter in the left upper lobe. A trans-
bronchial lung biopsy (TBLB) demonstrated adenocarci-
noma. She underwent left upper lobectomy with
systematic lymph node dissection using video-assisted
thoracoscopic surgery. The left superior pulmonary vein
(LSPV) was divided using a linear stapler at the point
where it branched to the superior segment, and the branch
to the lingular segment was ligated and divided. Thepostoperative course was uncomplicated. She was pre-
scribed oral tegafur/uracil as adjuvant chemotherapy and
followed up every 6 months. Enhanced CT showed a throm-
bus in the stump of the LSPV 19 months postoperatively
(Figure 1, A). Anticoagulant therapy was immediately
started, and CT 24 months postoperatively showed that
the thrombus had disappeared.
Patient 2
A 66-year-old man, who had continuously smoked 35
cigarettes per day for 30 years, underwent surgery and ra-
diotherapy for maxillary cancer in 1994, surgery for oro-
pharyngeal cancer in September 2002, and surgery for
tongue cancer in December 2002. Chest CT in September
2008 showed a mass 35 mm in diameter. Adenocarcinoma
was confirmed by TBLB. He was treated by video-
assisted thoracoscopic left upper lobectomywith systematic
lymph node dissection. The LSPV was divided using a lin-
ear stapler. The postoperative course was uncomplicated.
He was prescribed oral tegafur/uracil as adjuvant che-
motherapy and followed up using enhanced CT every 6
months. Enhanced CT showed a thrombus in the stump of
the LSPV 18 months postoperatively (Figure 1, B), but ce-
rebral infarction developed on the same day. Brain hernia-
tion, pneumonia, and acute renal failure followed, and he
died 19 months postoperatively.
Patient 3
A 53-year-old woman, who was a nonsmoker with no
medical history, underwent right nephrectomy to treat
right renal cell carcinoma in March 2005. Follow-up chest
CT in March 2010 showed a nodule 14 mm in diameter in
the left upper lobe. Adenocarcinoma was confirmed by
TBLB. She was treated by video-assisted thoracoscopic
left upper lobectomy with systematic lymph nodeardiovascular Surgery c Volume 143, Number 1 e3
